US-based pharmaceutical company Pfizer has announced plans to introduce Inflectra (infliximab-dyyb) for injection, a biosimilar of REMICADE (infliximab) in the US next month.
Inflectra will be the first biosimilar monoclonal antibody (mAb) in addition to only the second biosimilar to be available in the country, as well as being approved to treat adult and pediatric patients with moderate to severely active Crohn’s disease.
The product can also be used to treat adult patients with moderate-to-severely active ulcerative colitis who do not have an adequate response to conventional therapy.
Moderate-to-severely active rheumatoid arthritis in combination with methotrexate can be treated using Inflectra.
Furthermore, the product can be used to treat active ankylosing spondylitis, active psoriatic arthritis and chronic severe plaque psoriasis.
Pfizer essential health business regional president North America Diem Nguyen said: “By introducing Inflectra to the US marketplace, Pfizer is helping customers access an additional high-quality treatment option that promises greater savings for the healthcare system.
“We are proud of our global leadership in biosimilars, and will continue our efforts to advance a sustainable, competitive marketplace for these therapies to deliver a high-quality, consistent supply of product and long-term savings and value for patients and physicians.”
Pfizer said Inflectra is already introduced in other markets worldwide.